Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and PEG-Interferon Alfa-2B in Advanced Melanoma
NCT00027742Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2001
- Primary completion
- Jun 2005
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and peginterferon alfa-2b in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Response Rate and Toxicity Profile. Started May 2001; status: completed.
02
Drugs
temozolomidepeginterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00027742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027742.